View the latest news and SEC filings
Scroll to
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare Conference Date: Wednesday, June
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m.
LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
March 17, 2017 |
UPLOAD |
UPLOAD |
Other |
|
|
March 3, 2017 |
mendment to a previously filed DRS |
DRS/A |
Registration Statements |
|
|
February 13, 2017 |
A statement of beneficial ownership of common stock by certain persons |
SC 13G |
Other |
|
|
January 30, 2017 |
mendment to a previously filed DRS |
DRS/A |
Registration Statements |
|
|
December 21, 2016 |
UPLOAD |
UPLOAD |
Other |
|
|
November 23, 2016 |
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy |
DRS |
Registration Statements |
|
|
July 20, 2016 |
|
D |
Other |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
